- Home
- ENTX vs VEEA Comparison
ENTX vs VEEA Comparison
Compare ENTX & VEEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- VEEA
- Stock Information
- Founded
- ENTX 2010
- VEEA 2014
- Country
- ENTX Israel
- VEEA United States
- Employees
- ENTX N/A
- VEEA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- VEEA
- Sector
- ENTX Health Care
- VEEA
- Exchange
- ENTX Nasdaq
- VEEA NYSE
- Market Cap
- ENTX 104.0M
- VEEA 83.9M
- IPO Year
- ENTX 2018
- VEEA N/A
- Fundamental
- Price
- ENTX $1.86
- VEEA $1.64
- Analyst Decision
- ENTX Strong Buy
- VEEA
- Analyst Count
- ENTX 1
- VEEA 0
- Target Price
- ENTX $10.00
- VEEA N/A
- AVG Volume (30 Days)
- ENTX 40.5K
- VEEA 34.8K
- Earning Date
- ENTX 08-08-2025
- VEEA 08-23-2025
- Dividend Yield
- ENTX N/A
- VEEA N/A
- EPS Growth
- ENTX N/A
- VEEA N/A
- EPS
- ENTX N/A
- VEEA N/A
- Revenue
- ENTX $223,000.00
- VEEA $139,252.00
- Revenue This Year
- ENTX N/A
- VEEA N/A
- Revenue Next Year
- ENTX N/A
- VEEA N/A
- P/E Ratio
- ENTX N/A
- VEEA N/A
- Revenue Growth
- ENTX N/A
- VEEA N/A
- 52 Week Low
- ENTX $1.41
- VEEA $1.33
- 52 Week High
- ENTX $2.79
- VEEA $18.56
- Technical
- Relative Strength Index (RSI)
- ENTX 44.39
- VEEA N/A
- Support Level
- ENTX $1.91
- VEEA N/A
- Resistance Level
- ENTX $2.04
- VEEA N/A
- Average True Range (ATR)
- ENTX 0.10
- VEEA 0.00
- MACD
- ENTX 0.00
- VEEA 0.00
- Stochastic Oscillator
- ENTX 37.84
- VEEA 0.00
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About VEEA VEEA INC
Veea Inc is a company providing an edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. The company has first-in-class VeeaHub smart connectivity and computing hubs that integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.